Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 3;27(11):e917-e918.
doi: 10.1093/oncolo/oyac173.

SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research

Deniz C Guven  1 , Taha K Sahin  2 , Serkan Akın  1   3 , Fatih M Uckun  4
Affiliations

SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research

Deniz C Guven et al. Oncologist. .

Abstract

This letter to the editor responds to comments on a recently published article on seroconversion rates after COVID-19 vaccination.

PubMed Disclaimer

Comment in

  • doi: 10.1093/oncolo/oyac169
  • doi: 10.1093/oncolo/oyac032

References

    1. Sriwijitalai W, Wiwanitkit V.. Therapy in patients with hematologic malignancies, seroconversion rates, and SARS-CoV-2 vaccination. Oncologist. 2022;27:e916. - PMC - PubMed
    1. Guven DC, Sahin TK, Akın S, Uckun FM.. Impact of therapy in patients with hematologic malignancies on seroconversion rates after SARS-CoV-2 vaccination. Oncologist. 2022;27(4):e357-e361. 10.1093/oncolo/oyac032. - DOI - PMC - PubMed
    1. Sette A, Crotty S.. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861-880. 10.1016/j.cell.2021.01.007. - DOI - PMC - PubMed
    1. Le Bert N, Tan AT, Kunasegaran K, et al. . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457-462. 10.1038/s41586-020-2550-z. - DOI - PubMed
    1. Ehmsen S, Asmussen A, Jeppesen SS, et al. . Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2021;39(8):1034-1036. 10.1016/j.ccell.2021.07.016. - DOI - PMC - PubMed

Substances